HGH

GT-2000 Human Growth Hormone            4200 ng/ml  (700 ng/160 mcl spray)  GT-1000 Human Growth Hormone            2100 ng/ml  (335 ng/160 mcl spray)    GT-900X Human Growth Hormone     Growth Factor Complex of Lurong+HGH

GT-900 Human Growth Hormone    Colostrums  +  HGH 9X/30X +MSM     

GT-66x    Human Growth Hormone            600 ng/ml    (100 ng/160mcl spray)

GT-600  Human Growth Hormone              Homeopathic Chewable Tablets, 6C,100C, 

                                                                   and 200C

Growth hormone deficiency occurs when the pituitary gland does not secrete sufficient amounts of endogenous growth hormone. Adults may acquire this condition as a result of treatment of pituitary tumors, or from other medical conditions resulting in hypopituitarism -- it can also be a continuation of childhood-onset growth hormone deficiency. Growth hormone deficiency should be determined with an appropriate growth hormone stimulation test.

In vitro, preclinical and clinical studies have demonstrated Genotropin is therapeutically equivalent to human growth hormone of pituitary origin. In six placebo-controlled clinical studies of 172 GHD adults, 85 of whom received Genotropin, lean body mass, total body water and lean/fat ratio all increased while total body fat mass and waist circumference decreased after six months. These effects on body composition were maintained when treatment was continued beyond six months. Bone mineral density declined after six months of treatment but returned to baseline values after 12 months.

"There is medical evidence that indicates adults with GHD can benefit from growth hormone replacement therapy -- including those previously treated for GHD as children and those who are recognizing this condition for the first time," said Barbara Lippe, M.D., P&U's senior medical director, Peptide Hormones. "Both types of patients can realize physical improvements through therapy with Genotropin, while also having access to a range of patented, patient-friendly devices used to prepare and administer this medicine."
                                   

For adults, Genotropin is available in two-chamber cartridges containing 5.8 mg and 13.8 mg. Both cartridge sizes may be used with the Genotropin Pen growth hormone delivery devices and the Genotropin Mixer or the pre-assembled Intra-Mix growth hormone reconstitution devices. Treatment is administered six or seven times per week by a subcutaneous injection in the thigh, buttocks or abdomen. Dosage is adjusted for the individual patient.

In November 1996, Pharmacia & Upjohn submitted a New Drug Application for Genotropin to treat adults with GHD. The product has been in use in Europe to treat adults since 1993 and is available in 28 countries worldwide, including Sweden, Germany, the United Kingdom and Austria. Genotropin for use in treating GHD in children was cleared for marketing in the U.S. in August 1995.

In clinical trails, the most prevalent side effects in GHD adults treated with Genotropin were mild to moderate symptoms of fluid retention, including peripheral swelling, arthralgia, pain and stiffness of the extremities, peripheral edema, myalgia, paresthesia and hypoesthesia. Genotropin should not be used when there is any evidence of neoplastic activity, including intracranial lesions or tumors. Patients with diabetes or glucose intolerance would be monitored closely during treatment with Genotropin.